Anti-PD-1 and anti-PD-L1 antibodies also have fewer side effects than anti-CTLA-4 antibodies and are now authorized for the treatment of melanoma, lung carcinomas, renal carcinomas, bladder carcinomas, colon carcinomas, and Hodgkin lymphoma, amongst many other cancers [178]. The gene discussed is PDCD1; the disease is cancer.